Thera Vitae Ltd.

State-of-the-art cell therapies using the patient’s own cells to treat a variety of disorders, especially cardiovascular diseases

Thera Vitae is an international biotechnological company founded in 2003 by Robert Clark and Valentin Fulga. The company consists of three operating centers, in Israel, Thailand and Hong Kong. The centre in Israel focuses on research and manufacturing; the centre in Thailand on clinical development and marketing and the Hong Kong centre on financing issues.

Valentin Fulga, MD, CEO

Alexander Battler, Prof.
Michael Belkin, Prof.
Suphachai Chaithiraphan, Prof.
Aaron Ciechanover, Prof.
Tsvee Lapidot, Prof.
Ren-Ke Li, Prof.
John Marshall, Prof.
Naphtali Savion, Prof.

7 Pinhas Sapir Street, P.O. Box 4049
Ness Ziona 74140
Israel
Phone: +972-8-9409170
Fax: +972-8-9409167

The company hopes to use autologous angiogenic cell precursors (ACPs) expanded ex vivo in order to treat patients suffering from severe anginal syndrome who are not responsive to treatment. ACPs are aimed at promoting the formation of natural bypass blood vessels within the ischemic (not yet scarred tissue) and improve the conditions of such patients. Blood samples are collected from the patient, cells are isolated and grown. Specific conditions help the cells to differentiate into ACPs and proliferate. After this step, the cells are implanted by direct injection into the patients’ heart vessels where they build capillaries or differentiate into smooth muscle cells and cardiomyocytes. Currently, treatment can also be invisioned for ophthalmic disorders such as age-related macular degeneration, glaucoma or diabetic retinopathy.